Vera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERA research report →
Range $29 – $125
Price Chart
About the company
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection.
- CEO
- Marshall Fordyce
- IPO
- 2021
- Employees
- 362
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on VERA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.84B
- P/E
- -4.53
- Fwd P/E
- 9.02
- PEG
- 0.13
- P/S
- 188.19
- P/B
- 5.79
- EV/EBITDA
- -4.81
- Div Yield
- 0.00%
- Gross Margin
- 67.93%
- Op Margin
- -4160.07%
- Net Margin
- -4041.19%
- ROE
- -90.03%
- ROIC
- -104.28%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-315,473,000
- Net Income
- $-299,615,000-96.9%
- EPS
- $-4.66-69.5%
- OCF Growth
- -79.0%
- FCF Growth
- -78.2%
- 52W High
- $56.05
- 52W Low
- $25.08
- 50D MA
- $30.44
- 200D MA
- $35.79
- Beta
- 0.95
- RSI (14)
- 36
- Avg Volume
- 1.95M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vera Therapeutics reported a strong early TRUTAKNA launch, first-quarter commercial sales of $10.3 million, and submitted an sBLA seeking full approval based on positive ORIGIN 3 kidney outcomes.· November 5, 2026
- About 700 patient start forms have been received since the July 7 launch, which management said is their best early demand measure.
- TRUTAKNA’s ORIGIN 3 final analysis showed a 76% reduction in risk of kidney disease progression versus placebo through 104 weeks and preserved eGFR benefit across subgroups.
- Third-quarter net product revenue was $10.3 million, with about half characterized as demand and about half as inventory stocking.
- Management said payer coverage is improving and expects to reach 50% of covered lives by year-end.
- The company ended the quarter with $384 million in cash, cash equivalents and marketable securities and added $75 million of debt in late October.
Third-quarter 2026 net product revenue from TRUTAKNA was $10.3 million, the company’s first partial quarter of commercial sales. Cost of sales was $3.3 million. R&D expense was $41.3 million versus $56.5 million a year ago, reflecting lower contract manufacturing expense now capitalized as inventory after July 7 FDA accelerated approval. SG&A was $61.4 million versus $27.5 million in the prior-year period, mainly due to launch spending. Net loss was $93.7 million, or $1.30 per share, compared with a net loss of $80.3 million, or $1.26 per share a year ago. For the first 9 months of 2026, operating cash use was $305.9 million versus $171.1 million a year ago. As of September 30, cash, cash equivalents and marketable securities totaled $384 million; after a $75 million debt draw in late October, pro forma cash and securities would have been $459 million. Management did not give formal next-quarter or full-year revenue guidance; instead, it said net product revenue will become the primary launch metric going forward, alongside quarterly patient start forms. They also said they are on track to reach 50% of covered lives by the end of the year.
Marshall Fordyce framed the quarter as a turning point: TRUTAKNA is now launched, the company has moved quickly to seek full approval, and the product’s clinical package is broadening with ORIGIN 3 and PIONEER data. He highlighted the recent sBLA submission and said the company expects potential full FDA approval in mid-2027, with Europe to follow through a 1Q27 filing. His tone was upbeat and execution-focused, emphasizing urgency, discipline, and confidence that the ASN data will support the launch.
Sean Grant focused on the early commercial revenue base and the cost structure shift tied to launch. He reported $10.3 million of net product revenue, $3.3 million of cost of sales, $41.3 million of R&D, $61.4 million of SG&A, and a net loss of $93.7 million, then noted that manufacturing costs for commercial supply are now being capitalized as inventory rather than expensed in R&D. He said cash, cash equivalents and marketable securities were $384 million at quarter-end, with an additional $75 million drawn in late October and up to $350 million still available under the debt facility, giving the company flexibility to support the launch and trials.
Analysts focused on whether the post-ASN ORIGIN 3 presentation was already driving more demand; management said it was too early to see an inflection, but demand was continuing at a “nice pace” and ASN should be a Q4 catalyst. Other questions centered on the monthly dosing study, with management saying data from the de novo monthly cohorts are expected later this quarter, and on physician adoption, where management said the 700 start forms are not coming from a small number of doctors and are spread across high-volume nephrologists and academic centers. Payer access and patient mix also came up: management said it is on track for 50% covered lives by year-end and that early starts include both patients above and below 1 gram proteinuria, mostly from the prevalent treated pool rather than true treatment-naive patients.
Management sees a strong early launch with 700 patient start forms, improving access, and broad early use across the indicated patient pool. The ORIGIN 3 dataset is being positioned as a major validation step, and management said it should strengthen both adoption and the case for full approval.
Management repeatedly said it is still too early to tell how much of the launch is real pull-through versus stocking, and it has not yet seen a clear post-ASN inflection. Commercial execution still depends on payer coverage, nephrologist education, and access friction, while spending remains elevated and cash burn was substantial at $305.9 million in the first 9 months.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.8%
- Shares Outstanding
- 72.30M
- Float Shares
- 52.62M
of shares held by institutions
236 13F filers
Buy/sell ratio 0.43. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.73M | ▼ 18.87K |
| Avoro Capital Advisors LLC | 5.72M | ▼ 165.00K |
| Price T Rowe Associates Inc | 4.01M | ▼ 561.09K |
| Deep Track Capital, LP | 4.00M | ▼ 106.07K |
| Deerfield Management Company, L.P. | 3.92M | ▲ 194.30K |
| Vanguard Group Inc | 3.57M | ▲ 379.75K |
| State Street Corp | 3.30M | ▼ 846.89K |
| Kynam Capital Management, LP | 2.89M | ▼ 508.17K |
| Sofinnova Investments, Inc. | 2.79M | 0 |
| Fmr LLC | 2.79M | ▲ 18.07K |
| Vanguard Capital Management LLC | 2.71M | ▼ 44.16K |
| Eversept Partners, LP | 2.21M | ▲ 39.48K |
Held by 248 ETFs
Biggest fund positions in VERA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Fordyce Marshall | other | 18,500 |
| Sep 15, 26 | Fordyce Marshall | other | 18,500 |
| Sep 15, 26 | Fordyce Marshall | sell | 18,500 |
| Sep 11, 26 | Young Joseph R | other | 5,000 |
| Sep 11, 26 | Young Joseph R | other | 5,000 |
| Sep 2, 26 | Fordyce Marshall | other | 18,500 |
| Sep 2, 26 | Fordyce Marshall | other | 18,500 |
| Sep 2, 26 | Fordyce Marshall | sell | 18,500 |
| Jul 7, 26 | Fordyce Marshall | other | 46,250 |
| Jul 7, 26 | Fordyce Marshall | other | 46,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VERA coverage
Recent articles, reports, and earnings notes.
No research on VERA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VERA report →He Takes a New Job at 64 With a $100,000 Stock Grant. When the Shares Vest, Social Security Could Withhold His Retirement Checks Even Though He Hasn’t Sold a Single Share
247wallst.com · Nov 12
Vera Therapeutics, Inc. $VERA Shares Sold by CenterBook Partners LP
defenseworld.net · Nov 10
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
Vera Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.